证券日报网讯海辰药业（300584）10月10日在互动平台回答投资者提问时表示，截至9月30日，公司股 东数为22415户。 ...

从资金流向上来看，当日化学制药板块主力资金净流出11.08亿元，游资资金净流入5.65亿元，散户资金 净流入5.44亿元。化学制药板块个股资金流向见下表： 证券之星消息，10月9日化学制药板块较上一交易日下跌0.66%，南新制药领跌。当日上证指数报收于 3933.97，上涨1.32%。深证成指报收于13725.56，上涨1.47%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300584 | 海辰药业 | 63.81 | 13.76% | 15.58万 | 9.73亿 | | 300255 | 常山药业 | 49.29 | 8.21% | 39.44万 | 19.16亿 | | 600200 | *ST苏吴 | 1.00 | 5.26% | 48.36万 | 4553.49万 | | 603520 | 司太立 | 11.44 | 5.05% | 1 20.69万 | 2.38亿 | | 300705 | 九典制药 | 17.02 | 3.47% | 15.53万 ...

Investment Rating - The report maintains a "Buy" rating for the electric equipment and new energy industry [1] Core Insights - The lithium battery sector is experiencing a seasonal demand increase, with lithium carbonate and lithium hydroxide prices rising by 20% in September [1][6] - In August, domestic wholesale sales of new energy passenger vehicles reached 1.18 million units, reflecting a year-on-year increase of 22% and a month-on-month increase of 10% [1][4] - The report highlights the importance of solid-state battery technology and its potential breakthroughs in addressing interface issues, which are critical for commercialization [3][18] Summary by Sections Monthly Research Insights - The report discusses solutions to solid-solid interface issues in solid-state battery manufacturing, emphasizing the need for breakthroughs in physical, chemical, and mechanical dimensions [3][13] Industry Sentiment Tracking and Review - New energy vehicle sales in August showed strong growth, with China, Europe, and the US leading the market [4][22] - Domestic energy storage installations in August reached 12.6 GWh, a year-on-year increase of 58% [5][28] - The report forecasts a significant increase in lithium battery production in October, with year-on-year growth expected to be between 21% and 50% [5][34] Price and Volume Analysis - Lithium battery material prices are on the rise, with lithium carbonate and lithium hydroxide prices increasing by 20% in September [6][35] - The report notes that the lithium battery supply chain is entering a replenishment phase, with inventory levels rising [39] New Technology Developments - Solid-state batteries and composite current collectors are entering a critical engineering and industrialization phase, with significant orders expected for 2025 [6][44] - The report identifies key investment opportunities in solid-state battery technology, particularly in dry processing and isostatic pressing equipment [18][21] Investment Recommendations - The report recommends focusing on leading companies in the lithium battery sector and those involved in solid-state technology breakthroughs, such as CATL and EVE Energy [7][21]

证券之星消息，9月24日化学制药板块较上一交易日上涨0.13%，向日葵领涨。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 8.57 | 20.03% | 300.34万 | | 24.00亿 | | 002020 | 京新药业 | 21.63 | 10.02% | 27.78万 | | 5.81亿 | | 002294 | 信立泰 | 60.24 | 10.01% | 14.80万 | | 8.69% | | 300584 | 海辰药业 | 61.56 | 7.98% | 15.43万 | | 9.31亿 | | 688197 | 首药控股 | 48.28 | 6.93% | 3.02万 | | 1.41亿 | | 688302 | 海创药业 | 55.69 | 6.62% | 4.06万 | | 2.26亿 | | 00 ...

（文章来源：证券日报） 证券日报网讯 9月19日晚间，海辰药业发布公告称，公司于近日收到国家药品监督管理局核准签发的 《药品注册证书》，药品名称：硫代硫酸钠注射液。 ...

Group 1 - Huadian Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] - Cisco Ray's 2022 annual report was found to have inflated revenue by 9.96 million and profit by 7.0054 million, leading to penalties and a change in stock name to ST Cisco Ray [3] - Tianpu Co., Ltd. experienced a 245.20% increase in stock price over 13 consecutive trading days, indicating a risk of rapid decline [4] - ST New Power is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6] - Baoli International intends to invest in semiconductor testing equipment company Hongtai Technology, acquiring 1%-3% equity [7] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Shiqi Future, focusing on smart vision technology [8] Group 2 - SF Holding reported a revenue of 24.787 billion yuan in August, a year-on-year increase of 7.86% [9] - Various companies are involved in share transfers, including Guangli Micro and *ST Tianlong, with plans for significant asset restructuring [11] - Xinwangda's subsidiary aims to establish a storage industry fund with professional investment institutions [12] - Several companies are planning share repurchases, including Shunhao Co. and Lingyun Optics, with adjustments to repurchase plans [18]

Group 1 - Honghe Technology plans to increase capital by 300 million yuan to its wholly-owned subsidiary Huangshi Honghe through debt-to-equity conversion, raising its registered capital from 700 million yuan to 1 billion yuan [1] - Huaxia Happiness has completed debt restructuring amounting to approximately 192.67 billion yuan, with a total of 24 billion yuan in overdue debts as of August 31 [1] - Chengyi Pharmaceutical's controlling shareholder plans to reduce its stake by up to 1.18%, amounting to 387,560 shares [1][2] Group 2 - Yuanwang Valley received a warning letter from the Shenzhen Securities Regulatory Bureau for failing to halt trading when its controlling shareholder's stake changed to a multiple of 5% [2] - Gongjin Co. received government subsidies of 8.9 million yuan, accounting for 11.13% of its latest audited net profit [3] - Maiwei Biotech's application for the listing of 9MW0813 injection has been accepted by the National Medical Products Administration [4] Group 3 - Jianfeng Group plans to repurchase shares worth between 20 million and 40 million yuan at a maximum price of 12.42 yuan per share [6] - Ankai Micro plans to invest 20 million yuan to acquire a 4% stake in Shiqi Future [7] - Pinming Technology's stock will continue to be suspended as it is actively pursuing a significant matter that may lead to a change in control [8] Group 4 - China Communications has signed new contracts worth 256.34 billion yuan from January to August, with domestic contracts totaling 206.05 billion yuan [18] - Round Express reported a revenue of 5.39 billion yuan in August, a year-on-year increase of 9.82% [38] - China Pacific Insurance's original insurance premium income reached 217.05 billion yuan from January to August, up 13.2% year-on-year [39] Group 5 - *ST Chuangxing's chairman is under investigation, and the general manager will act as the chairman during this period [40] - Fengshan Group signed a technical development contract with Tsinghua University for a project related to sodium-ion battery electrolytes [40] - Yongxin Optical stated that its optical components related to lithography machines account for less than 1% of its revenue [41] Group 6 - Tianyuan Dike's subsidiary received a government subsidy of 3.77 million yuan, representing 16.27% of its latest audited net profit [42] - Huaxiang Co. plans to issue convertible bonds to raise no more than 1.308 billion yuan for various projects [43] - Wolong Electric Drive reported that its robot-related products accounted for only 2.71% of total revenue in the first half of the year [44]

格隆汇9月19日丨海辰药业(300584.SZ)公布，近日收到国家药品监督管理局核准签发的《药品注册证 书》，药品名称：硫代硫酸钠注射液。本品适应症为：主要用于氰化物中毒，也可用于砷、汞、铅、 铋、碘等中毒。硫代硫酸钠被认为是硫氰酸酶（Rhodanese）催化的反应中的硫供体，从而增强氰化物 的内源性解毒作用。 ...

Core Viewpoint - Hainan Pharmaceutical has received approval from the National Medical Products Administration for the registration of Sodium Thiosulfate Injection, which is primarily used for cyanide poisoning and can also be used for poisoning from arsenic, mercury, lead, bismuth, and iodine [1]. Group 1 - The drug name is Sodium Thiosulfate Injection [1] - The primary indication for the drug is cyanide poisoning [1] - The drug is also applicable for other types of poisoning, including arsenic, mercury, lead, bismuth, and iodine [1] Group 2 - Sodium thiosulfate is considered a sulfur donor in the reaction catalyzed by rhodanese, enhancing the body's endogenous detoxification of cyanide [1]

人民财讯9月19日电，海辰药业（300584）9月19日公告，公司于近日收到国家药品监督管理局核准签发 的《药品注册证书》。药品名称为硫代硫酸钠注射液，规格：50ml:12.5g，本品适应症为：主要用于氰 化物中毒，也可用于砷、汞、铅、铋、碘等中毒。 ...